secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000886163-25-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand leads $75M royalty financing for Castle Creek's D-Fi gene therapy Phase 3 trial
--------------------------------------------------------------------------------

- Ligand invested $50M and led syndicate of co-investors totaling $75M for high single-digit royalty on D-Fi worldwide sales.
- Castle Creek to use funds for Phase 3 trial of D-Fi (gene therapy) for dystrophic epidermolysis bullosa (DEB).
- Ligand also acquired $8.3M subordinated promissory note for $1.8M, due upon FDA approval of D-Fi.
- Co-investors include Paragon Biosciences, Valor Equity Partners, and XOMA Royalty Corp. (Nasdaq: XOMA).
- Warrants to purchase Series D-1 Preferred Shares exercisable until 2035.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000003/0000886163-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000003/lgnd-20250224.htm
  HTML page:      https://secwatch.observer/filing/0000886163-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer